The p53 family of proteins includes three members, p53, p63, and p73. The protein p63 is encoded by TP63 gene, which gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (deltaNp63) of an N-terminal transactivation domain. Immunohistochemistry of p63 has a clinical relevance for certain tumor types, but investigations have been hampered by a lack of well characterized antibodies that are specific for p63, do not cross-react with the related p53 and p73 proteins, and allow for discrimination between p63 isoforms TAp63 and deltaNp63 with opposite functional properties.
Lyn is a Src-family protein tyrosine kinase that is predominantly expressed in hematopoietic cells. It is associated with a number of cell surface receptors including the B cell antigen receptor (BCR) and Fc receptors. Upon their triggering, Lyn phosphorylates subunits of these receptors in a cholesterol-dependent manner, utilizing the plasma membrane lipid raft system. The phosphorylated intracellular domains of the receptors are accessible for cytoplasmic Syk tyrosine kinase, which is activated by Lyn-mediated phosphorylation and which transduces the signal to downstream adaptors. Lyn is abnormally distributed in acute myeloid leukemia cells and seems to be a novel pharmacologic target of this disease.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Bacterially expressed recombinant fragment of human Lyn (aa 8 - 238).
Applications:
IP,WB,ICC
Additional Info:
The antibody LYN-01 reacts with Lyn (p56/p53), a non-receptor Src-family tyrosine kinase expressed in hematopoietic tissues (intracellular antigen).
Clone number:
LYN-01
Antibody Isotype:
IgG1
Application Details:
Western blotting: Recommended dilution: 1-2 ?g/ml.
Ku Antigen (DNA-dependent DNA helicase) is a heterodimer (of 72 and 87 kDa polypeptides) which contributes to genomic integrity through its ability to bind DNA double-strand breaks and facilitate repair by the nonhomologous end-joining pathway. A DNA double-strand break is a major lesion that destroys the integrity of the DNA molecule. Such damage is introduced by ionizing radiation. Ku binds to free double-stranded DNA ends and is the DNA-binding component of the DNA-dependent protein kinase. Thus, the Ku protein is involved in DNA repair and in V(D)J recombination, and the Ku-DNA-dependent protein kinase complex may have a role in those same processes. Ku70 and Ku80 share a common topology and form a dyad-symmetrical molecule with a preformed ring that encircles duplex DNA. The binding site can cradle 2 full turns of DNA while encircling only the central 3-4 base pairs. Ku makes no contacts with DNA bases and few with the sugar-phosphate backbone, but it fits sterically to major and minor groove contours so as to position the DNA helix in a defined path through the protein ring. These features are well designed to structurally support broken DNA ends and to bring the DNA helix into phase across the junction during end processing and ligation. Mouse cells deficient for Ku80 display a marked increase in chromosomal aberrations, including breakage, translocations, and aneuploidy. Despite the observed chromosome instabilities, Ku80 -/- mice have only a slightly earlier onset of cancer. Loss of p53 synergizes with Ku80 to promote tumorigenesis such that all Ku80 -/- and p53 -/- mice succumb to disseminated pro-B-cell lymphoma before 3 months of age. The p70/p80 complex binds to the ends of double-stranded DNA in a cell cycle-dependent manner, being associated with chromosomes of interphase cells, followed by complete dissociation from the condensing chromosomes in early prophase. Some patients with systemic lupus erythematosus produce very large amounts of autoantibodies to p70 and p80. The autoantibody has been found in patients with autoimmune thyroid disease (Graves disease) as well as in those with lupus.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
human whole T-lymphocytes
Applications:
ICC,IP
Additional Info:
The antibody MEM-54 reacts with Ku80, a 80 kDa subunit of Ku autoantigen (heterodimer of 72 and 87 kDa intracellular polypeptides). Ku autoantigen is involved in DNA repair and in V(D)J recombination through its ability to bind DNA double-strand breaks.
The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
KLH-conjugated phosphopeptide RHKKLMFKTEGPDS[P]D, corresponding to amino acids 378-393 of human p53.
Applications:
WB,IHC
Additional Info:
The mouse monoclonal antibody FP3.2 [FPS392] reacts with human p53 tumour suppressor intracellular protein phosphorylated at CKII site (Ser 392).
Clone number:
FP3.2 [FPS392]
Antibody Isotype:
IgG1
Application Details:
Immunohistochemistry (paraffin sections): Standard ABC technique (DAB+), pretreatment: high temperature antigen retrieval (microwave, pressure cooker) in 10 mM citrate buffer pH 6.0 or 1 mM EDTA-NaOH buffer pH 8.0, recommended dilution: 10 ?g/ml, incubation: 1 hour at RT; or overnight at 4°C, positive tissue: breast carcinoma with high level of wild-type p53. Western blotting: recommended dilution: 1 ?g/ml.
PPM1D is a Mg2+/Mn2+ dependent protein phosphatase 1D with inducible expression in response to various types of environmental stress. This expression is p53-dependent, and subsequently PPM1D negatively regulates the p53-mediated transcription, thus it suppresses the apoptosis. PPM1D contributes to development of carcinomas, and seems to be a promissing therapeutic target. Amplification of PPM1D is associated with breast cancer.
The p53 family of proteins includes three members, p53, p63, and p73. The protein p63 is encoded by TP63 gene, which gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (deltaNp63) of an N-terminal transactivation domain. Immunohistochemistry of p63 has a clinical relevance for certain tumor types, but investigations have been hampered by a lack of well characterized antibodies that are specific for p63 and do not cross-react with the related p53 and p73 proteins.
The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Bacterially expressed full-length wild-type p53
Applications:
FC,IP,WB,IHC,ICC,ELISA
Additional Info:
The antibody BP53-12 recognizes a defined epitope (aa 16-25) on human p53, a 50 kDa intracellular tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer.
The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Immunogen:
Bacterially expressed full-length wild-type p53
Applications:
FC
Additional Info:
The antibody BP53-12 recognizes a defined epitope (aa 16-25) on human p53, a 50 kDa intracellular tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer.
The tumour suppressor p21Waf1 (wild-type p53-activated fragment 1; also known as Cip1, Cdk interacting protein, or SDI 1) is a cyclin-dependent kinase (Cdk) inhibitor, which is expressed by involvement of p53, Egr-1, AP2, STATs or other transcription factors upon various stimuli resulting in cell cycle arrest. Through its N-terminal domain p21Waf1 inhibits Cdk activity, whereas through the C-terminal domain it inhibits the activity of PCNA (proliferating cell nuclear antigen) to activate DNA replication. Cytosolic location of p21 counteracts its inhibitory activities.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Human p21 protein
Applications:
IHC,ICC,ELISA
Additional Info:
The antibody WA-1 reacts with p21 protein (Waf1, Cip1, SDI 1; intracellular antigen), a 21 kDa tumour suppressor, which inhibits the activity of cyclin-dependent family kinases and of proliferating cell nuclear antigen.
The p53 family of proteins includes three members, p53, p63, and p73. The protein p73 is encoded by TP73 gene, which gives rise to protein isoforms with different properties and functions due to the presence (TAp73) or absence (deltaNp73) of an N-terminal transactivation domain. Investigations have been hampered by a lack of well characterized antibodies that are specific for p73 and do not cross-react with the related p53 and p63 proteins, as well as a lack of antibodies that specifically recognize either the TAp73 or deltaNp73 variants. We are introducing now such a set of antibodies.
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Human T lymphocytes.
Applications:
FC,IP,WB,IHC,FA
Additional Info:
The antibody MEM-59 recognizes a neuraminidase-sensitive extracellular epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.
Clone number:
MEM-59
Antibody Isotype:
IgG1
Application Details:
Functional application: The antibody MEM-59 activates T lymphocytes and also induces apoptosis in hemopoietic progenitor cells. Flow cytometry: Recommended dilution: 1 ?g/ml. Immunohistochemistry (paraffin sections): Positive tissue: spleen, thymus, tonsil; recommended dilution: 10 ?g/ml.
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Human T lymphocytes.
Applications:
FC,IP,WB,IHC
Additional Info:
The antibody MEM-59 recognizes a neuraminidase-sensitive extracellular epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Immunogen:
Human T lymphocytes.
Applications:
FC
Additional Info:
The antibody MEM-59 recognizes a neuraminidase-sensitive extracellular epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.
Clone number:
MEM-59
Antibody Isotype:
IgG1
Application Details:
Flow cytometry: The reagent is designed for analysis of human blood cells using 20 ?l reagent / 100 ?l of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Immunogen:
Human T lymphocytes.
Applications:
FC
Additional Info:
The antibody MEM-59 recognizes a neuraminidase-sensitive extracellular epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.
Clone number:
MEM-59
Antibody Isotype:
IgG1
Application Details:
Flow cytometry: The reagent is designed for analysis of human blood cells using 20 ?l reagent / 100 ?l of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Human T lymphocytes.
Applications:
FC,IP,WB,IHC
Additional Info:
The antibody MEM-59 recognizes a neuraminidase-sensitive extracellular epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.
Cdk1 (cyclin-dependent kinase 1), also known as p34Cdc2 (cell division control protein kinase 2) depends on cyclin A and B and is triggered by a positive feedback loop at the end of G2 phase, which is the key event that initiates mitotic entry. Destruction of cyclin B during metaphase results in inactivation of Cdk1, allowing mitotic exit and cell division. Cdk1 also contributes to the control of DNA replication. Cdk1 can be ihibited by several transcriptional targets of p53, such as p21WAF.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Bacterially expressed full-length human Cdk1 protein
Applications:
IP,WB,IHC,ICC
Additional Info:
The antibody POH-1 specifically detects Cdk1 (p34Cdc2; an intracellular antigen). Staining of Cdk1 reflects the proliferating potential of respective tissue.
AGR3 (Anterior Gradient 3) protein, also known as AG3 (hAG-3, HAG3 in human), or BCMP11, is a secreted cytoplasmic protein which is involved in metastasis induction and p53 tumour supressor inhibition. It may serve as molecular marker and potential therapeutic target for hormone-responsive breast tumours. Its Xenopus homolog is associated with anteroposterior fate determination during early development.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Purified human AGR3 protein
Applications:
WB,IHC,ICC
Additional Info:
The antibody AGR3.1 recognizes the epitope HETTDKNLS within the AGR3 (AG3) protein (19-20 kDa); a secreted cytoplasmic protein which can serve as a marker of carcinogenesis.
Clone number:
AGR3.1
Antibody Isotype:
IgG1
Application Details:
Immunohistochemistry (paraffin sections): Recommended dilution: 1 ?g/ml; positive tissue: breast cancer. Immunohistochemistry (frozen sections): Recommended dilution: 1 ?g/ml; positive tissue: breast cancer. Western blotting: Recommended dilution: 1 ?g/ml; positive control: T47D breast cancer cell line, negative control: H1299 lung carcinoma cell line. Immunocytochemistry: Recommended dilution: 1 ?g/ml; positive control: T47D breast cancer cell line, negative control: H1299 lung carcinoma cell line.
AGR2 (Anterior Gradient 2), also known as AG2 (hAG-2, HAG2 in human), or GOB-4, and AGR3 (Anterior Gradient 3), also known as AG3 (hAG-3, HAG3 in human), or BCMP11, are secreted cytoplasmic proteins which are involved in metastasis induction and p53 tumour supressor inhibition. They may serve as molecular markers and potential therapeutic targets for hormone-responsive breast tumours; AGR2 was reported also as a marker of other carcinomas. Xenopus homolog of these proteins is associated with anteroposterior fate determination during early development.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
Store at 2-8°C. Do not freeze.
Immunogen:
Purified human AGR3 protein
Applications:
WB,IHC,ICC
Additional Info:
The antibody AGR3.4 recognizes the PLMII epitope of AGR3 (AG3) and AGR2 (AG2) proteins (19-20 kDa); secreted cytoplasmic proteins which can serve as markers of carcinogenesis.
Clone number:
AGR3.4
Antibody Isotype:
IgG1
Application Details:
Immunohistochemistry (paraffin sections): Recommended dilution: 5 ?g/ml; Positive tissue: human colon. Western blotting: Recommended dilution: 1 ?g/ml; positive control: T47D breast cancer cell line, negative control: H1299 lung carcinoma cell line. Immunocytochemistry: Recommended dilution: 1 ?g/ml; positive control: T47D breast cancer cell line, negative control: H1299 lung carcinoma cell line.
Biosite Brand:
BioSite Flow
Conjugation:
Unconjugated
Concentration:
1 mg/ml
Species Reactivity:
human
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
